Mouse Monoclonal CD180 Antibody

CD180. also known as LY64 or RP105. is a member of the Toll-like receptor (TLR) family that plays a role in immune regulation. Unlike canonical TLRs, CD180 lacks the Toll/IL-1 receptor (TIR) signaling domain and is primarily expressed on B cells and dendritic cells. It forms a heterodimer with MD-1. which stabilizes its surface expression and modulates signaling pathways. CD180 is implicated in B-cell activation, survival, and antigen presentation, though its exact ligand and downstream mechanisms remain partially unclear. Antibodies targeting CD180 are valuable tools for studying its function in immune responses and disease contexts. Research suggests CD180 may influence autoimmune disorders, lymphoma progression, and inflammatory conditions by interacting with TLR4 or altering B-cell receptor signaling. CD180 antibodies are used in flow cytometry, immunohistochemistry, and functional assays to explore its role in immune cell dynamics and potential therapeutic targeting. Recent studies highlight its differential expression in certain cancers, linking it to tumor microenvironment interactions. However, its dual role as both an immune activator and suppressor, depending on cellular context, underscores the complexity of CD180 biology. These antibodies continue to aid in unraveling its contributions to immune homeostasis and pathological states.